Exploring the Use of Immunotherapy Techniques in Lymphocytic Leukemia

Abstract

This paper explores the complex interplay between the immune system and Lymphocytic Leukemia (CLL and ALL). It highlights the crucial role of immunology in understanding and combating this cancer. CLL is a cancer of white blood cells that disrupts healthy blood cell production. The paper details the causes, types, and treatments for CLL. It emphasizes the role of genetic mutations and underscores the higher risk in developed nations. Immunotherapy emerges as a promising strategy to fight CLL. The paper discusses immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR) T cell therapy. These techniques harness the body's immune system to target and destroy cancer cells. The paper explores the mechanisms by which CLL cells evade immune detection and how immunotherapy disrupts these strategies. It details the success and limitations of CAR T cell therapy, including its high cost and potential side effects. Finally, the paper explores ongoing clinical trials using Blinatumomab, a drug targeting minimal residual disease in ALL. This research exemplifies the continuous advancements in immunotherapy for Leukemia.